2 Result: SCYNEXIS
Q2: SCYNEXIS Surpasses Forecasts; Nogin Misses the Mark
August 14th, 2023
SCYNEXIS, Inc. (Nasdaq: SCYX), a biotechnology company, reported second-quarter 2023 earnings of $2.46 per share, surpassing the consensus estimate of $1.55 per share. The company posted quarterly sales of $131.50 million, exceeding analysts' project. Read more
Major Announcements in the Industry: Momentus Secures SpaceX Deal, Clearmind Medicine Receives Trial Approval, and SCYNEXIS Enters Exclusive License Agreement with GSK
May 12th, 2023
In recent updates, several companies have made significant announcements in their respective fields. Here's a breakdown of the latest developments: Momentus Inc. (Nasdaq: MNTS) has entered into a contract with SpaceX, securing a port reservation o. Read more
Want To Find Some News?
News By Industries
Recent Post
-
DOT, DoW, DHS Join Forces to Protect Southern Border Airspace
October 16th, 2026FTC Sues Ticket Broker Over Unlawful Tactics Used to Buy Millions of Tickets to Popular Live Events
October 15th, 2026October 15th, 2026FDA Approves First Treatment for Certain People With BCG-Unresponsive Bladder Cancer
October 14th, 2026U.S. Treasury Announces Record Enforcement Actions Against Bank of America
October 14th, 2026
Member Login